NCT02119221View on ClinicalTrials.gov

Copanlisib Mass Balance Study

PHASE1CompletedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

April 30, 2014

Study Completion Date

October 31, 2014

Conditions

Healthy Volunteers

Interventions

DRUG

Copanlisib (BAY80-6946)

Intravenous infusion of 12 mg copanlisib labeled with 2.76 MBq (75 μCi) of \[14C\]

Trial Locations (1)

9471 GP

Zuidlaren

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY